What’s Next for MannKind Corp.?

MannKind's inhaled insulin product Afrezza was recommended for approval by an FDA panel yesterday, causing shares to double in after-hours trading. Should you hold or take profits?

Apr 2, 2014 at 9:00AM

The long and meandering regulatory pathway for MannKind's (NASDAQ:MNKD) inhaled insulin product Afrezza may be close to its journey's end after two overwhelmingly positive votes by the U.S. Food and Drug Administration's, or FDA's, Endocrinologic and Metabolic Drugs Advisory Committee yesterday. To recap, the committee voted 13 to 1 in favor of Afrezza for type I diabetes, and voted 14 to 0 for type 2 diabetes. The panel's decidedly favorable view of Afrezza is somewhat surprising because an FDA reviewer raised several concerns over missing data, modest efficacy, and an imbalance of lung cancers in the briefing documents. Indeed, the market certainly feared the worst after the documents were released last week, as MannKind shares dropped over 35% in short order. Although the FDA doesn't have to follow the recommendation of the panel, it usually does. So, MannKind investors may be in for more good news on or before April 15, which is Afrezza's target PDUFA action date. 

What's particularly interesting is that this the second time already this year that the FDA has released briefing documents that appeared to contain major hurdles to a drug's approval, only for the advisory committee to vote strongly in favor of approval. As a refresher, Chelsea Therapeutic's anti-fainting drug Northera looked dead in the water after the briefing documents openly recommended the drug be rejected because of deficiencies in the clinical trial design and execution. Yet, the advisory committee ended up voting 16-1 in favor of Northera, with it receiving final approval from the FDA soon thereafter. If past is prologue, Afrezza may thus get the green light from the FDA for both type 1 and type 2 diabetes within the next two weeks.

What's next?
In after-hours trading following the positive vote, MannKind's shares rose approximately 110%, giving the company a market cap exceeding $3 billion. Previously, I discussed how post-approval trading patterns for biotechs like MannKind are notoriously hard to predict, and this case looks to be no different. The foremost issue is the large number of unknowns facing MannKind and its inhaled insulin product going forward. While final approval appears to be likely after such a strong recommendation by the panel, my view is that the market is going to want clarity on the commercialization front soon. Specifically, MannKind's management has made it clear that they intend on partnering for Afrezza. As MannKind currently lacks the resources to take a go-it-alone approach toward marketing Afrezza, the near-term prospects for MannKind's shares may depend on how a partnership is structured.

Possible issues holding up a partnership
First and foremost, I believe the peak sales estimates of Afrezza could be a sticking point in the negotiations. Almost immediately after the news broke yesterday, Bloomberg reported that three analysts they had polled estimated 2018 sales of $534 million. If this estimate turns out to be a starting point in negotiations, you can see how a big pharma may not be particularly inclined to ink a deal that is front-loaded with large milestone payments. And MannKind could counter that such estimates are too conservative given that Novo Nordisk (NYSE:NVS) and Eli Lilly's (NYSE:LLY) injected insulins garnered a combined $5.6 billion in sales last year, according to Bloomberg. Put another way, the Street is saying that Afrezza will be a specialty niche drug compared to Novolog and Humalog, whereas MannKind's management may hold an entirely different opinion altogether. Time will tell how this issue plays out. However, if you believe the market is a predictor of future performance, it's worth noting that this news didn't move the needle on shares of either Novo Nordisk or Eli Lilly, suggesting that the market may not believe that Afrezza will be a major competitor in the insulin space.  

Foolish wrap-up
With the regulatory smoke starting to clear, the fog of commercialization is surely to set in on MannKind's near-term outlook. Looking ahead, you can rest assured that the bulls and bears will debate this issue until they're both blue in the face. In short, I think the only certainty following this positive advisory committee vote is that MannKind shares will continue to be volatile moving forward. As such, I believe risk-averse investors may want to remain cautious given that the market assigned the company a $3 billion plus market cap in after hours trading, and Afrezza's commercial prospects may not be able to support this lofty valuation, at least in the near term. Given the twists and turns of MannKind's tale, however, I wouldn't be surprised if Afrezza once again proved its detractors wrong.

Boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

     

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers